CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity Aug 24, 2020
CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference Aug 5, 2020
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 Jul 30, 2020
